Table 1.

Cohort characteristics among patients who received trimodality therapy (TMT) for muscle invasive bladder cancer, stratified by receipt of neoadjuvant chemotherapy (NAC).

		TMT N=2104		NAC+TMT N=462
Variable	Level	N	%	N	%	P-value*
Age at Diagnosis	<60	147	7.0	48	10.4	0.001
	60–69	362	17.2	97	21.0
	70–79	703	33.4	160	34.6
	80+	892	42.4	157	34.0
Race	White	1876	89.2	413	89.4	0.700
	Black	128	6.1	29	6.3
	Asian-Indian-Pacific	30	1.4	9	1.9
	Hispanic	43	2.0	8	1.7
	Other/unknown	27	1.3	3	0.6
Year	2004–2006	447	21.2	84	18.2	0.315
	2007–2009	514	24.4	107	23.2
	2010–2012	457	21.7	113	24.5
	2013–2015	686	32.6	158	34.2
Charlson-Deyo Score	0	1340	63.7	300	64.9	0.613
	1+	764	36.3	162	35.1
Clinical T stage	T2	1728	82.1	389	84.2	0.289
	T3–4	376	17.9	73	15.8
Residence	Metro	1698	80.7	360	77.9	0.591
	Urban	310	14.7	79	17.1
	Rural	41	1.9	10	2.2
	Unknown	55	2.6	13	2.8
Insurance	Other	151	7.2	28	6.1	0.099
	Private	344	16.3	94	20.3
	Medicare	1609	76.5	340	73.6
Median income	< $38,000	335	16.0	67	14.6	0.325
	$38,000-$47,999	510	24.4	124	27.0
	$48,000-$62,999	597	28.6	141	30.7
	>=$63,000	647	31.0	127	27.7
No high school degree (%)	≥21.0%	304	14.5	62	13.4	0.318
	13.0–20.9%	503	24.1	127	27.5
	7.0–12.9%	769	36.8	172	37.3
	<7.0%	514	24.6	100	21.7
Facility	Non-academic	1536	73.1	328	71.1	0.401
	Academic	566	26.9	133	28.9
Region	Northeast	531	25.3	99	21.5	0.190
	South	662	31.5	142	30.8
	Midwest	571	27.2	145	31.5
	West	338	16.1	75	16.3
Travel distance (miles)	<25	1740	83.3	378	82.0	0.650
	25–50	210	10.0	53	11.5
	>50	140	6.7	30	6.5
TURBT (weeks from dx)	Median (IQR)	0.0	0.0–2.0	0.0	0.0–2.0	0.593
Chemo start (weeks from dx)	Median (IQR)	8.1	5.7–12	4.0	0.0–7.4	<0.001
Radiation start (weeks from dx)	Median (IQR)	8.1	5.9–12	14.6	9.7–18.9	<0.001
Total radiation dose	Median (IQR)	64.5	59.4–64.8	64.8	59.4–64.8	0.796

^*P-value by ANOVA for numerical covariates and chi-square test for categorical covariates

Abbreviations: TURBT, transurethral resection of bladder tumor; DX, diagnosis; IQR, intraquartile range